Atlas Venture — Full Portfolio

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

GGreg(Co-founder & Senior Vice President of Discovery Research)MMark(Co-founder & Senior Vice President of Medicinal Chemistry)MMike(President & CEO)CCharlotte(Chief Medical Officer)EElena(Chief Financial Officer)CCaroline(Chief Business Officer)

Co-investorsOROrbiMedRARA CapitalVIViking Global

Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.

BiotechDeep TechMedical DevicesCambridge, US

FZFeng Zhang(Founder)inGCGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDLDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKBKatrine Bosley(Executive Officer, Director)inVMVic Myer(Executive Officer)in

Board seatKBKevin Bitterman· per SEC Form D · $120M raise · filed Aug 2015

Co-investorsECEcoR1 CapitalGVGV (Google Ventures)SOSofinnova VenturesVIViking GlobalDEDeerfield Management CompanyFLFlagship Ventures+2 more

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

NBNessan Bermingham(Founder)inJennifer Doudna(Founder)JRJose Rivera(Executive Officer)inJLJohn Leonard(President and Chief Executive Officer)inJBJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEDEdward Dulac(Executive Vice President, Chief Financial Officer)in

Board seatJFJean-François Formela· per SEC Form D

Co-investorsAGage1AVAvoro Capital AdvisorsECEcoR1 CapitalFOForesite CapitalOROrbiMedRIRidgeback Capital+1 more

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

JHJustin Hanes(Director)inKPKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTBTodd Bazemore(Executive Officer)inMIMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Board seatKBKevin Bitterman· per SEC Form D · $7M raise · filed Aug 2015

Co-investorsLOLongitude CapitalSRSR One Capital ManagementWEWellington ManagementYSYsios CapitalLULux CapitalRARA Capital+1 more

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.

BiotechHealthtechCambridge, US

NBNessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJFJean-François Formela(Director)inOCOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRARam Aiyar(Chief Executive Officer, President and Director)inTCTodd Chappell(Chief Operating Officer)in

Board seatJFJean-François Formela· per SEC Form D

Co-investorsMCMC Healthcare VenturesNENew Enterprise Associates (NEA)ALAlexandriaQIQiming Venture PartnersQIQiming Venture Partners USARORock Springs Capital+3 more

Neuronetics manufactures and sells the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation device used in office-based treatment of major depressive disorder and other mental health conditions, along with operating a network of treatment centers that provide both NeuroStar therapy and esketamine treatment to patients.

HealthtechMalvern, US

Mark R. Bausinger(Executive Officer)inCTChristopher Thatcher(Executive Officer, Director)inDaniel L. Reuvers(President and Chief Executive Officer)

BoardStephen Campe(Director)Robert Kuhling(Director)Liam Ratcliffe(Director)

Board seatKBKevin Bitterman· per SEC Form D · $34.3M raise · filed May 2015

Co-investors131315 CapitalASAscension VenturesWEWestern Technology InvestmentCHCHV CapitalGEGE Ventures

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

AMAnkit Mahadevia(Executive Officer, Director)inSGStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in

BoardJFJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)

Board seatJFJean-François Formela· per SEC Form D

Co-investorsGVGV (Google Ventures)HEHEALTHCARE ROYALTY PARTNERSMRMRL Ventures FundOUOUP (Osage University Partners)RARA CapitalALAlphabet+1 more

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

RRRené Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKLKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)

Board seatDGDavid Grayzel· per SEC Form D · $95M raise · filed Feb 2021

Co-investorsBABain Capital Life SciencesBABay City CapitalF-F-Prime CapitalM M VenturesMRMRL Ventures FundRARA Capital+9 more

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical DevicesCambridge, US

JMJohn Maraganore(Founder)inPSPhillip Sharp(Founder)David Bartel(Founder)Thomas Tuschl(Founder)Paul Schimmel(Founder)Phillip Zamore(Founder)

Co-investorsARARCH Venture PartnersBLBlackstone Life SciencesCACardinal PartnersINInvivo Capital PartnersALAlexandria

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge, GB

GWGregory Winter(Director)inNCNIGEL CROCKETT(Executive Officer)inNKNICHOLAS KEEN(Executive Officer)SASANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in

Co-investorsAHAhren Innovation CapitalASAstellas Venture Management LLCCACambridge Innovation CapitalDEDementia Discovery FundLOLongwood FundRIRidgeback Capital+4 more

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

JQJohn Quisel(Chief Executive Officer)inJFJean Franchi(Chief Financial Officer)inJYJonathan Yu(Chief Operating Officer)inWSWill Savage(Chief Medical Officer)inPSPamela Stephenson(Chief Commercial Officer)inSCSteve Caffé(Chief Regulatory Officer)in

Co-investorsACAccess BiotechnologyBABain Capital Life SciencesFOForesite CapitalFRFrazier Life SciencesOROrbiMed5A5AM Ventures+7 more

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOBOxana Beskrovnaya, Ph.D.(Executive Officer)JGJohn G. Cox(President and Chief Executive Officer)in

Co-investorsMPMPM BioImpactVIVida VenturesWEWellington ManagementFOForbionHEHercules Capital, Inc.RARA Capital

Exelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types.

BiotechHealthtechSan Francisco Bay Area, US

Michael M. Morrissey(President and Chief Executive Officer)inChristopher J. Senner(Executive Vice President and Chief Financial Officer)

Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.

BiotechHealthtechMedical DevicesNew Brunswick, US

EMEdward Mead JohnsonJWJames Wood JohnsonRWRobert Wood Johnson IJDJoaquin DuatoinJ. Duato(Chief Executive Officer)

Co-investorsAIAisling CapitalNANaviMed CapitalPOPortland Seed FundSPSPRINGROCK VENTURESTHThe Column GroupVEvenBio Partners

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

NMNello Mainolfi(Founder)inBBBruce Booth(Chair)in

Co-investorsAVAvoro Capital AdvisorsBABain Capital Life SciencesBEBessemer Venture PartnersHAHatteras Venture PartnersMRMRL Ventures FundNENextech Invest+7 more

miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.

BiotechBoulder, US

William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in

Co-investorsBRBrace PharmaBRBroadview VenturesMCMC Healthcare VenturesRIRidgeback CapitalBOBoulder VenturesHEHeartland+1 more

Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.

BiotechHealthtechMedical Devices

Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)

Co-investorsBABain Capital Life SciencesFOForesite CapitalREREDMILE

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

BCBharatt Chowrira(Executive Officer)inMSMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)inPMPaul Miller(Executive Officer)inABAoife Brennan(Executive Officer)inTSTodd Shegog(Executive Officer)in

Co-investorsCLCLI VenturesNENew Enterprise Associates (NEA)NSNSG VenturesPFPfizer Venture InvestmentsSOSofinnova VenturesSOSolasta Ventures+1 more

Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation.

BiotechDigital HealthHealthtechLongevityMedical DevicesCambridge, US

Charles Wilson(Executive Officer, Director)CSChristiana Stamoulis(Executive Officer)inAndrew Robbins(Chief Executive Officer, President and Director)inJohn Green(Chief Financial Officer)inEKEvan Kearns(Chief Legal Officer and Corporate Secretary)inCole Pinnow(Chief Commercial Officer)in

Co-investorsF-F-Prime CapitalSASanofi Ventures

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

AFAdam Friedman(Chief Executive Officer)inAFAndrew Fedder(Executive Officer, Director)inBPBrian Piper(Executive Officer, Director)in

Board seatJFJean-François Formela· per SEC Form D

Co-investorsLILightspeed Venture PartnersVIVida VenturesOMOmega FundsTETenmileABAbingworthALAlleyCorp+1 more

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.

BiotechFemTechHealthtechConcord, US

MYMike Young(Founder)inTST Scott Johnson(Founder)inPAPaul Antinori(Executive Officer)AAAllison August(Executive Officer)inThomas Scott Johnson(Executive Officer, Director)

BoardBBBrendan Bulik-Sullivan(Director)in

Board seatDGDavid Grayzel· per SEC Form D

Co-investorsGVGV (Google Ventures)BRBroadview VenturesF-F-Prime CapitalLILilly Asia VenturesNENew Enterprise Associates (NEA)

IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer.

BiotechHealthtechCambridge, US

GDGary D. Glick(Founder)inHMH. Martin Seidel(Chief Executive Officer)in

BoardJFJean-Francois Formela(Director)in

Board seatJFJean-François Formela· per SEC Form D

Co-investorsABAbingworth

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

RHRoger Heerman(Chief Business/Operating Officer / Co-Founder)inFMFrazer Morgan(Chief Development Officer / Co-Founder)inRCRobert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

BoardJBJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Board seatKBKevin Bitterman· per SEC Form D

Co-investors5A5AM VenturesRARA CapitalEQEQT Life SciencesGIGimvSISixty Degree CapitalVIVivo Capital+3 more

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)inRGRobert Gagnon(Executive Officer)HWHeather Wasserman(Executive Officer)inMPMatthew Patterson(Director)inSBScott Biller(Director)in

Board seatKBKevin Bitterman· per SEC Form D

Co-investorsFOForesite CapitalTHThe Column GroupARARCH Venture PartnersALAlexandriaDEDecheng Capital

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

PTPatrick Trojer(President & Chief Executive Officer)in

Board seatDGDavid Grayzel· per SEC Form D

Co-investorsASAscenta CapitalLILightspeed Venture PartnersRARA CapitalBEBessemer Venture PartnersPFPfizer VenturesFIFinchley Healthcare Ventures+3 more

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

PTPraveen Tipirneni(Chief Executive Officer)LWLiangsu Wang(Chief Scientific Officer)ZLZhong Liu(Chief Technology Officer)APAaron Pelta(Chief Business Officer)CWColm White(Chief Program Officer)

Co-investorsJAJanus Henderson InvestorsLALAVVEvenBio PartnersWEWellington Management

Curileum develops regenerative medicine therapies targeting intestinal stem cells to prevent colorectal cancer.

BiotechHealthtechMedical DevicesLondon, GB

DJDr Jeff Moore(Founder & CEO)

Co-investorsBIBiotechnology Value FundCACanaan PartnersPRProspect Venture PartnersOXOxford Technology Management

Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.

BiotechHealthtechCambridge, US

NKNiranjan Kameswaran(Chief Executive Officer)inJSJessica Stromme(Chief Development Officer)inKFKelly Foster(Chief Scientific Officer)inSHStephen Huang(Senior Vice President, Head of Clinical Development)in

BoardSRSimon Read(Chairman of the Board and Independent Board Member)in

Co-investorsAVAvoro Capital AdvisorsMEMedicxi

Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.

BiotechHealthtechCambridge, US

AFAndrew Fraley(Judo Bio Co-Founder)inASAlfica SehgalinOCOMMER CHOHAN(Executive Officer)inJAMES JEFFREY GOATER(Executive Officer, Director)SRSimon Read(Executive Chair and Acting CEO)inWHWilliam Ho

Co-investorsDIDigitalis VenturesDRDroia VenturesTHThe Column GroupYKYK Bioventures

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtechBurlington, MA, US

JRJay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)AOArthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)

Co-investorsARARCH Venture PartnersSASanofi Ventures5A5AM Ventures

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical DevicesBoston, US

LGLuke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)DLDavid Liu, PhD(Founder)ALAngelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)JWJonathan Weissman, PhD

Co-investorsNENewpath Partners5A5AM VenturesARARCH Venture PartnersDCDCVC (Data Collective)F-F-Prime CapitalGVGV (Google Ventures)+11 more

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsBIBiotechnology Value FundFOForbionLILightspeed Venture PartnersREResearch Corporation TechnologiesTCTCG Crossover

Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.

BiotechDeep Tech

RDRajesh Devraj(President and Chief Executive Officer)inRHRobert Hughes(Chief Scientific Officer)inPBPol Boudes(Chief Medical Officer)

Co-investorsDCDC Investment PartnersLOLongwood FundFOForbion

Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.

BiotechHealthtechMedical Devices

BRBernard Ravina(Founder and Chief Executive Officer)inJDJudy Dunn(President of Research & Development)JFJessica Fees(Chief Financial Officer)inADAriel D. Jasie(Chief Business Officer and General Counsel)inTMTushar Misra(Chief Technical Officer)in

Co-investorsFRFrazier Life SciencesACAccess IndustriesACAccess BiotechnologyCACanaan Partners

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.

AI & Machine LearningBiotechDeep TechWaltham, US

Luc Vandenberghe(Director)ATAaron Tward, M.D., Ph.D.(Scientific Co-Founder)BRBotond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)RDRami Daoud(Executive Officer)inRMRick Modi(Chief Executive Officer, Board Member)

Board seatDGDavid Grayzel· per SEC Form D

Co-investorsECEcoR1 CapitalEIEight Roads VenturesF-F-Prime CapitalGVGV (Google Ventures)NENew Enterprise Associates (NEA)TCTCG Crossover

nChroma Bio is a genetic medicines company developing in vivo therapies that pair genetic cargoes with targeted delivery technologies.

BiotechLongevityBoston, US

Angelo Lombardo(Founder)David R. Liu(Founder)J. Keith Joung(Founder)Jonathan S. Weissman(Founder)Luigi Naldini(Founder)Luke Gilbert(Founder)

Board seatKBKevin Bitterman· per SEC Form D · $135M raise · filed Sep 2023

Co-investorsOUOUP (Osage University Partners)WEWellington ManagementCACasdin CapitalGVGV (Google Ventures)NENewpath Partners

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.

BiotechHealthtechSouth San Francisco, US

Jeremy Bender(Executive Officer, Director)

BoardDDDerek DiRocco(Director)inJPJulie Papanek Grant(Director)inJJJohn Josey(Director)inDaniel Becker(Director)

Board seatMGMichael Gladstone· per SEC Form D

Co-investorsACAccess BiotechnologyCACanaan PartnersVIViking GlobalACAccess IndustriesRARA CapitalTHThe Column Group

GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.

BiotechDeep TechHealthtechCambridge, US

Daniel J Mandell(Chief Executive Officer)TLTracey Lodie(Executive Officer)inChristopher Gregg(Director)

BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)

Board seatKBKevin Bitterman· per SEC Form D · $60.4M raise · filed Jul 2024

Co-investorsLELeaps by BayerREREDMILEALAlumni VenturesDIDigitalis VenturesDRDreamers VCRIRising Tide+3 more

BiotechCambridge, US

Rick Lundberg(Executive Officer)GPGeorge P. Vlasuk(Executive Officer, Director)in

BoardJFJean-Francois Formela(Director)inACAlan Crane(Director)inMNMarian Nakada(Director)inBGBrian Gallagher(Director)in

Board seatKBKevin BittermanJFJean-François Formela· per SEC Form D

Co-investorsAGage1BRBrace PharmaSASanofi VenturesPOPolaris PartnersSRSR One Capital Management

BiotechCambridge, US

Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)

BoardBrian Gallagher(Director)JFJean- Francois Formela(Director)inJoshua Resnick(Director)

Board seatJFJean-François Formela· per SEC Form D

Co-investorsPFPfizer Venture Investments

Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).

BiotechHealthtechBerkeley, US

Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)TGThomas Gustafson(Executive Officer)inECEmily Conley(Executive Officer, Director)in

BoardECEvan Caplan(Director)inCharlotte McKee(Director)

Board seatKBKevin Bitterman· per SEC Form D

Co-investors5A5AM VenturesOROrbiMedQIQiming Venture PartnersQIQiming Venture Partners USA

BiotechBoston, US

AFAdam Friedman(Executive Officer, Director)inGGGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDSDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)

Board seatJFJean-François Formela· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsECEcoR1 CapitalFRFrazier Life SciencesNENextech InvestVIVida VenturesABAbingworth+3 more

Co-investorsNENeva Sgr.SOSofinnova PartnersXGXGEN VentureFOForbionLOLongwood Fund

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsDRDroia VenturesECEcoR1 CapitalGVGV (Google Ventures)THThe Column GroupABAbbVieJJJJDC+3 more

Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtech

Co-investorsBABain Capital Life SciencesRARA CapitalSOSofinnova VenturesFOForbion

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsFOForesite CapitalFRFrazier Life SciencesGEGeneral AtlanticLILifeSci Venture PartnersSCScion Life SciencesTHThe Innovation Space+2 more

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsMIMission BiocapitalPFPfizer Venture InvestmentsPFPfizer VenturesPIPivotal Life Sciences

Co-investorsALAlta PartnersARARCH Venture PartnersDCDC Investment PartnersLOLongwood FundNENextech InvestPAPathway to Cures+6 more

Become provides a technology platform that matches small and medium-sized businesses with tailored funding options using advanced algorithms.

FintechMarketplacesSaaS

Co-investorsENEntrée Capital

Bluespec develops tools and IP for hardware and embedded systems developers, with a focus on RISC-V technology for core evaluation, software development, acceleration, and verification.

Deep TechDeveloper ToolsHardwareSemiconductorsFramingham, US

AMArvind Mithal(Director)Charles Hauck, Jr.(Executive Officer, Director)PPPaul Pedevillano(Executive Officer)inCHCharlie Hauck(Chief Executive Officer)inBrian McAloon(Director)DLDave Lemont(Director)in

Co-investorsACAccompliceNONorth Bridge Venture Partners & Growth Equity

The site presents a multi-day conference about application and web design, covering design theory, tools, product design roles, and current web design trends.

Media & Entertainment

Co-investorsBABantam GroupBOBoston Seed CapitalLALaunchCapital

Cadent Therapeutics was a Cambridge, Massachusetts-based neuroscience company developing clinical-stage therapies for neuropsychiatric disorders including schizophrenia, movement disorders, and treatment-resistant depression.

BiotechDigital HealthHealthtechMedical DevicesCambridge, US

Co-investorsQIQiming Venture Partners USASLSlater Technology FundACAccess IndustriesCLClal Biotechnology IndustriesCOCowen Healthcare InvestmentsNONovartis Institute for Biomedical Research+1 more

Waltham, US

Patrick Morley(Executive Officer, Director)inEric Pyenson(Executive Officer)Gordon Pothier(Executive Officer)Ben Johnson(Founder)Michael Viscuso(Founder)

BoardRonald Nordin(Director)

Co-investors.4.406 VenturesACAccompliceAGAgman PartnersEVEvolution Equity PartnersFOFounders Circle CapitalINIntel Capital+7 more

Chill.com publishes wellness content focused on stress, recovery, sleep, and gut health, with references to supplements for supporting the body under sustained stress.

ConsumerImpact & Social GoodMedia & EntertainmentWellness & Fitness

Brian NorgardDan Gould

Co-investors50500 GlobalKLKleiner PerkinsLOLowercase CapitalRERedpoint Ventures

Verizon is a telecommunications company that provides wireless services and connectivity solutions to consumers and businesses.

Cloud ComputingEnterprise SoftwareNew York, US

Co-investorsMAMatrixNONorth Atlantic CapitalNONorwest Venture Partners

Advertising technology platform providing audience-based sales for television advertising.

Somerville, US

Joshua Summers(Executive Officer, Director, Promoter)Doug Hurd(Executive Officer, Director, Promoter)in

BoardRyan Moore(Director)LALars Albright(Director)in

Co-investorsBOBoston Seed CapitalTRTransmedia CapitalTRTribeca Venture PartnersDAData Point CapitalFRFreestyle CapitalWEWestern Technology Investment

Cohere develops customer engagement software that guides users visually on their screens during support and sales interactions, including over voice and text channels like phone or chat.

AI & Machine LearningEnterprise SoftwareSaaSNew York City, US

YLYunyu Lin(Founder)inRSRahul Sengottuvelu(Founder)inJason Wang

Co-investorsDEDe Fi Alliance HoldingsINInovia CapitalRARadical VenturesSASalesforce VenturesY Y CombinatorBOBoxGroup+8 more

A marketplace where independent designers sell digital assets such as fonts, graphics, templates, photos, and themes to other creators.

Developer ToolsEnterprise SoftwareMarketplacesSan Francisco, US

D"Darius "Bubs" Monsef(Founder)inAEAaron Epstein(Founder)inCWChris Williams(Founder)inCWChris Winn(Executive Officer, Director)in

BoardCack Wilhelm(Director)

Co-investors50500 GlobalFOFounder CollectiveONOnStartupsY Y CombinatorACAccompliceALAlexis Ohanian+17 more

CustomMade is a custom jewelry design and creation service that works with clients to create bespoke pieces, including bridal, heirloom redesign, and fine jewelry.

B2B MarketplacesConsumerDirect to ConsumerE-commerceDover, US

SRSeth Rosen(Executive Officer, Director)in

BoardDavid Hauser(Director)Sasha Shusteff(Director)

Co-investorsNENextView VenturesWEWestern Technology InvestmentFIFirst Round CapitalFOFounder CollectiveGVGV (Google Ventures)LALaunch Capital+1 more

deCODE analyzes and interprets the human genome to identify genetic risk factors for common diseases including cardiovascular disease and cancer.

AI & Machine LearningBiotechDeep TechReykjavik, IS

KSKári Stefánsson(Founder)in

Co-investorsARARCH Venture Partners

DeepScale developed efficient deep neural network software for perception systems in autonomous vehicles, optimized to run on low-power automotive-grade processors.

Mountain View, US

Sri Chandrasekar(Director)Forrest Iandola(Executive Officer, Director)Kurt Keutzer(Director)

Co-investorsAUAutotech VenturesNENext47TRTrucks VC1111.2 CapitalCOCota Capital

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Alex Lugovskoy(Founder and Chief Executive Officer)inMichael Gladstone(Founder)

Co-investorsECEcoR1 CapitalFRFrazier Life SciencesRARA CapitalRVRV Invest GmbHSASanofi VenturesVIViking Global

DisplayLink develops USB graphics system-on-chip technology that enables multiple display expansion across Windows, macOS, ChromeOS, Ubuntu, and Android devices regardless of underlying hardware architecture.

Enterprise SoftwareHardwareSemiconductors

Martin King(Founder)Quentin Stafford-Fraser(Founder)

Co-investorsBABalderton CapitalDADag VenturesWEWestern Technology InvestmentCICipio PartnersPRPrelude Ventures

CybersecurityCambridge, US

Co-investorsBABantam GroupTETechstars

Earnest develops microbial seed coatings and agricultural biology products derived from prairie ecosystems to improve soil health and crop performance for farmers.

AgTechBiotechRantoul, US

EMEddy Mejia(Co-founder)inDGDr. Gabe Price(Co-founder)

Co-investorsAGAg Ventures AllianceAGAgLaunch AcceleratorBOBoot64 VenturesSOSOSVADAdams Street PartnersANAndreessen Horowitz+4 more

Egalet develops medicines for people living with moderate to severe pain, including approved and licensed pain products.

BiotechHealthtechMedical DevicesWayne, US

BARBARA A. CARLIN(SENIOR VICE PRESIDENT AND CHIEF ACCOUNTING OFFICER)ROBERT S. RADIE(CHIEF EXECUTIVE OFFICER)MARK STROBECK(EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER)MEGAN TIMMINS(SENIOR VICE PRESIDENT AND GENERAL COUNSEL)PATRICK M. SHEA(SENIOR VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER)Jeffrey M. Dayno(Chief Medical Officer)

Co-investorsSUSunstone Capital

EnglishCentral is an online English language learning platform offering videos and courses for learners.

AI & Machine LearningEdTechSaaS

ASAlan Schwartz(Founder & CEO)inIan Park(President & Board Member)

Co-investorsBABantam GroupVAValor Capital Group

Boston, US

Co-investorsTETechstarsMIMilitello Capital

Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.

BiotechCambridge, US

JMJames McLaughlin(Executive Officer, Director)in

BoardJGJean George(Director)JRJason Rhodes(Director)inCGCarl Gordon(Director)in

Co-investorsALAltium CapitalLILightstone VenturesOROrbiMed

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)MAMark Angelino(Executive Officer)

BoardJRJason Rhodes(Director)inCSCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsFOForesite CapitalWEWellington ManagementCACasdin CapitalDEDeerfield Management CompanyF-F-Prime CapitalFIFidelity Investments+1 more

Advanced ManufacturingDeep TechFintechHardwareSaaSCambridge, US

Indrek Narusk(Founder)inHMHardi Meybaum(Founder)in

BoardDSDavid Skok(Director)in

Co-investorsASAsimov VenturesHEHeuristic Capital PartnersMAMatrixNENextView VenturesTETechstarsTETera Ventures

Stratasys develops polymer 3D printing systems and software for product design, prototyping, and manufacturing across aerospace, automotive, healthcare, and other industries.

Advanced ManufacturingHardwareNew Materials

Co-investorsLELerer HippeauMAMatrixNENextView Ventures

Influencer marketing platform connecting brands with social content creators for performance-measured, whitelisted paid social campaigns.

Cambridge, US

Brendan Lattrell(Executive Officer, Director)

BoardDavid Balter(Director)

Co-investorsBABantam GroupKAKae CapitalRIRiverwalk HoldingsTETechstars

Grapevine operates a platform for Giving Circles that enables groups to pool donations, manage members, and direct funds to nonprofits.

Impact & Social GoodSaaSSocial

EREmily RasmusseninJessan Hutchinson-Quillian

Co-investorsDIDiagram CapitalGAGaingelsKAKae CapitalNONotation CapitalOVOverton Venture CapitalPJPJC+4 more

Grapevine builds software that acts as a purchasing agent for healthcare buyers, comparing vendors, prices, and supply routes in real time to lower the cost of medical supplies.

B2B MarketplacesDigital HealthHealthtechLogistics & Supply ChainSaaSNew York, US

LYLuká Yancopoulos(CEO & Co-Founder)in

Co-investorsTHThe MBA FundPEPeak XV Partners

Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.

Cambridge, US

LJLeslie J Williams(Executive Officer, Director)

BoardBenjamin Chen(Director)SMSeiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)SGSteven Gillis(Director)in

Co-investorsARARCH Venture Partners5A5AM Ventures8V8VCPAPanacea VentureTATaiho Ventures, LLCTATakeda Ventures

Travel technology company partnered with Capital One Travel.

Montreal

FLFrederic Lalonde(Founder)Joost Ouwerkerk(Founder)

Co-investorsACAccompliceAGAgman PartnersBRBrightspark VenturesCACapital One VenturesDRDream Maker VenturesDRDrive Capital+11 more

Amgen is a pioneer in biologic medicine development using living cells to create treatments for serious illnesses with limited existing options.

BiotechHealthtech

Co-investorsAVAvoro Capital AdvisorsNENew Enterprise Associates (NEA)

HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.

AI & Machine LearningBiotechHealthtech

BoardBBBruce Booth(Chairman)in

Co-investorsB B Capital GroupB4B4 CapitalMRMRL Ventures FundPIPivotal Life SciencesSOSofinnova PartnersSOSolasta Ventures+2 more

IFM is an investment manager focused on long-term value creation across listed and non-listed assets, emphasizing sustainable competitiveness and stakeholder value alongside financial returns.

FintechSector AgnosticLuxembourg, LU

Co-investorsINInterogo Holding AG

ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases.

BiotechHealthtechSan Diego, US

Co-investorsOROrbiMed

Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.

BiotechHealthtechMedical DevicesSeattle, US

DBDavid Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJHJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in

Co-investorsAIAisling CapitalHMHM Venture PartnersOUOUP (Osage University Partners)SASanderling VenturesSASanofi VenturesSPSPRINGROCK VENTURES+4 more

Influitive provides a SaaS platform and professional services for customer advocate marketing, helping companies discover and mobilize their customer advocates to drive sales and customer lifetime value.

Marketing TechMedia & EntertainmentSaaS

MOMark Organ(Founder)inPAPuneet ArorainRSRich Stollerin

Co-investors50500 GlobalEXExtreme Venture PartnersEXExtreme Venture Partners LLPGOGolden VenturesHUHummer Winblad Venture Partners (HWVP)ILIlluminate Ventures+8 more

Integral Ad Science provides advertising verification and quality assurance solutions for digital advertisers and platforms.

AdTechAI & Machine LearningData & InfrastructureMarketing TechNew York, US

LJLidiane Jones(Chief Executive Officer)inACAmit Chaturvedi(Chief Operating Officer)inSGSrishti Gupta(Chief Product Officer)inTJThomas Joseph(Chief Technology Officer)inLNLisa Nadler(Chief Human Resources Officer)inYAYossi Almani(Chief Legal Officer)in

Co-investorsACAccompliceAUAugust CapitalCRCross Creek AdvisorsFOFounder CollectiveGOGolub GrowthLOLobby Capital+7 more

JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis.

Digital HealthHealthtechMedical DevicesIrvine, US

HFHans Figulla(Director)Markus FerrariVictoria Carr-Brendel(Executive Officer, Director)David Drachman(Executive Officer, Director)John Kilcoynein

BoardAKArnd Kaltofen(Director)in

Co-investorsANAndera PartnersBABain Capital Life SciencesRORosetta Capital Ltd.VIVI PartnersGIGimvINInnovatus Capital Partners+5 more

A biotechnology company developing cancer therapies for patients with unmet medical needs.

BiotechHealthtech

Co-investorsF-F-Prime CapitalNENextech InvestEIEight Roads Ventures

Kailera develops obesity management medications, including GLP-1 and multi-agonist receptor peptides and small molecules, with a global development pipeline led by injectable and oral formulations of ribupatide.

BiotechHealthtechMedical Devices

Co-investorsBABain Capital Life SciencesCACatalio Capital Management, LP

Ron Renaud(Founder)

Cambridge, US

SSSravish Sridhar(Executive Officer, Director)in

BoardFrank Castellucci(Director)Braden Bohrmann(Director)William Burnham(Director)Jon Karlen(Director)BBBrady Bohrmann(Director)

Co-investorsAVAvalon Ventures Management, LlcBABantam GroupNTNTT DOCOMO VenturesTETechstarsVEVerizon Ventures

Lagoa is a Canadian company that runs a cloud-based platform for creating and rendering 3D content.

Construction Tech

Arno ZinkeDov AmihodThiago Costa

Co-investors50500 GlobalRHRho Ventures

Lysosomal Therapeutics Inc.

BiotechCambridge, US

Dimitri Krainc(Director)Robert Carpenter(Executive Officer, Director)Cornelis Been(Executive Officer, Director)

BoardSteven Hall(Director)Carole Nuechterlein(Director)inBernard Davitian(Director)

Co-investorsSASanofi VenturesHAHatteras Venture PartnersLILilly VenturesOMOmega FundsRORoche Venture Fund

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsACAccess BiotechnologyNENextech InvestACAccess IndustriesFOForbionRARA Capital

Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.

BiotechCambridge, US

Andre Turenne(Executive Officer, Director)in

BoardJHJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)

Co-investorsACAccess BiotechnologyDIDigitalis VenturesSASanofi VenturesACAccess IndustriesALAlexandria

Matchpoint Therapeutics is a drug discovery company developing precision small molecule covalent medicines to treat immune and inflammatory diseases.

AI & Machine LearningBiotechDeep Tech

Andre TurenneJared Cumming(PhD)Christopher HrenThomas Durand-Reville(PhD)Wei Li(MD)Paola Castaldi(PhD)

Co-investorsSASanofi VenturesDIDigitalis Ventures

BiotechHealthtech

Jean-Paul Kress, M.D.in

Co-investorsBABayern KapitalRIRidgeback Capital

Plastiq enables businesses to pay vendors using credit cards while vendors receive payments via wire, ACH, check, or other methods, combined with embedded payment processing and card acceptance solutions for merchant transactions.

FintechSan Francisco, US

EBEliot Buchanan(Executive Officer, Director)inDCDaniel Choi(Executive Officer)inGWGeoffrey Willison(Executive Officer)inMMMichail Medvinsky(Executive Officer)in

BoardRyan Moore(Director)JBJeffrey Bussgang(Director)in

Co-investorsACAcorn Pacific VenturesBLBling CapitalFLFlybridge Capital PartnersPAParade VenturesSOSocii CapitalACAccomplice+5 more

Advanced ManufacturingMobility & TransportationAnn Arbor, US

LNLihang Nong(Founder)inErik Kauppi(CTO)Parke Wiegman(Manager)

Co-investorsGAGaingelsY Y CombinatorADAdditionBABackend CapitalCOConscience VCCOCory Levy+5 more

Nimbus provides automated cost optimization for Datadog customers, reducing their observability expenses without requiring manual intervention from engineering teams.

AI & Machine LearningData & InfrastructureEnterprise SoftwareSeattle, US

KLKevin Lin(Founder)inBernhard Echte(Founder)LNLihang Nong(Founder)inKiran Pathakota(COO)

Co-investorsY Y CombinatorALAltaclub VCALAltaIR CapitalCOCommunity Access FundFIFirst Rays Venture PartnersFOFoothill Ventures+4 more

HireNimbus is a mobile platform that connects homeowners with vetted local home service professionals for booking, payment, and job tracking.

AI & Machine LearningFintechImpact & Social GoodMarketplacesPropTechSaaSAlexandria, US

SSSatadru Sengupta(Founder)in

Co-investorsSASamvid VenturesTETechstarsGVGV (Google Ventures)

Nimbus Engineering is a hardware company and online retailer developing energy transfer technology, including its patented Power Relay, a portable power outlet for home, office, and outdoor use.

CleantechDeep TechEnergyHardwareSan Francisco, US

Michael Gorman(Founder)in

Co-investorsFOFoothill VenturesACAccess BiotechnologyBABain Capital Life SciencesBIBiotechnology Value FundCOCommodore CapitalGVGV (Google Ventures)+2 more

FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.

AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US

Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)

Co-investorsPRPre-Seed to SucceedYEYellow Rocks!ACAccess BiotechnologyBABain Capital Life SciencesBIBiotechnology Value FundCOCommodore Capital+3 more

Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.

AI & Machine LearningBiotechDeep TechHealthtech

Co-investorsACAccess BiotechnologyBABain Capital Life SciencesDEDementia Discovery FundGVGV (Google Ventures)LILightstone VenturesPFPfizer Venture Investments+4 more

NxStage provides home dialysis products and support for people with chronic kidney disease and end-stage renal disease, including home hemodialysis and peritoneal dialysis.

Digital HealthHardwareHealthtechMedical DevicesLawrence, US

Co-investorsCRCross Creek AdvisorsLOLongitude CapitalADAdams Street PartnersLILightspeed Venture Partners

Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.

BiotechHealthtech

PBPeter Barrett(Co-founder & Board Member)inTWTom Wandless(Scientific Founder)MJMadan Jagasia(Chief Executive Officer)inPHParameswaran Hari(Chief Medical Officer)inJFJulie Feder(Chief Financial Officer)inDADana Alexander(Chief Technical Officer)in

Co-investorsTCTCG CrossoverVEVertex Ventures HCWEWellington Management

PillPack is a full-service pharmacy that organizes and delivers medications to customers, managing automatic refills and coordinating directly with doctors and insurance providers.

Digital HealthHealthtechManchester, US

TPTimothy Parker(Chief Executive Officer, Director)inECElliot Cohen(Chief Technology Officer, Director)inTPTJ Parker(Founder)in

BoardDFDavid Frankel(Director)inJon Karlen(Director)Fred Destin(Director)

Co-investorsACAccelACAccompliceACACME CapitalBOBoxGroupCRCRV (Charles River Ventures)ENEntrée Capital+12 more

Digital banking and financial services for small businesses

Daniel Choi(Founder)Eliot Buchanan(Founder)

Co-investorsACAccompliceACAcorn Pacific VenturesALAlumni VenturesBLBling CapitalFIFirebolt Ventures Management Company, LlcFJFJ Labs+9 more

Recorded Future provides cyberthreat intelligence and AI-powered cyber defense capabilities to help organizations identify and neutralize critical threats.

AI & Machine LearningCybersecurityData & InfrastructureEnterprise SoftwareSomerville, US

CAChristopher Ahlberg(Founder)inSTStaffan Truve(Director)Staffan Truvé(Founder)

BoardLiautaud Bernard(Director)RMRich Miner(Director)inJeff Fagnan(Director)

Co-investorsACAccompliceBABalderton CapitalBABaukunstGUGula Tech AdventuresGVGV (Google Ventures)INIn-Q-Tel+4 more

HealthtechCambridge, US

Adam Rosenberg(Executive Officer, Director)inAMAnkit Mahadevia(Founder)in

BoardBBBruce Booth(Director)inKees Been(Director)Samantha Singer(Director)

Co-investorsGVGV (Google Ventures)HAHatteras Venture PartnersTHThird Point VenturesJJJJDCRERemeditex Ventures

Boston-based biotech developing drugs against the 'dark genome'/repeatome for autoimmune disease, cancer and neurodegeneration.

Benjamin Greenbaum(Founder)David Ting(Founder)Rosana Kapeller(Founder)

Co-investorsANAndreessen HorowitzARARCH Venture PartnersGVGV (Google Ventures)LULuma GroupSASanofi VenturesABAbingworth+11 more

New York, US

Edward Kim(Executive Officer, Director)KKKent Krekorian(Executive Officer)inHMHal Muchnick(Executive Officer, Director)in

BoardBo Peabody(Director)Benjamin Sun(Director)KWKirk Wolfe(Director)in

Co-investorsMIMI VenturesSOSocial StartsMKMK CapitalSPSpring Mountain Capital

Spero Therapeutics is a clinical-stage biopharmaceutical company developing next-generation immunology and inflammation medicines, particularly targeting patients with serious diseases and major treatment gaps.

BiotechHealthtechCambridge, US

Co-investorsHEHEALTHCARE ROYALTY PARTNERSTHThe Kraft Group

Sqrrl was a Cambridge, Massachusetts cybersecurity startup that built a threat-hunting platform based on Apache Accumulo, an NSA-derived big-data database technology, to help enterprises detect and investigate cyber threats.

Cambridge, US

Adam Fuchs(Executive Officer)Ely Kahn(Executive Officer, Director)Mark Terenzoni(Executive Officer, Director)Jeff Williams(Director)

BoardARAntonio Rodriguez(Director)inZHZenas Hutcheson(Director)in

Co-investorsALAlumni VenturesRARally Ventures Management, LlcMAMatrix

Co-investorsBABain Capital Life SciencesGEGeneral AtlanticOROrbiMed

Trace Neuroscience is a biotech company developing genetic medicines that restore UNC13A protein function to treat amyotrophic lateral sclerosis (ALS), with a lead antisense oligonucleotide program targeting UNC13A mRNA splicing.

BiotechHealthtech

Pietro Fratta(Scientific Co-founder)

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

VPVishal Patelin

Co-investorsASAscenta CapitalBOBorealis VenturesBOBorealis VenturesMAMagnetic VenturesOROrbiMedVIViking Global+4 more

FintechBoston, US

Co-investorsBABantam GroupGVGV (Google Ventures)TETechstarsBOBoston Seed CapitalCOCounterview Capital

Co-investorsTCTCG CrossoverADAditum Bio

An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.

AI & Machine LearningBiotechMedical DevicesCambridge, US

IMIvana Magovcevic-Liebisch(Executive Officer, Director)CVChristopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)

Co-investorsLILightstone VenturesPIPivotal Life SciencesVIVida VenturesHAHatteras Venture PartnersLOLongwood Fund

Vurb is a mobile search app that lets people find, save, and act on recommendations for things like travel, entertainment, and dining by combining community suggestions, content, and services in one app.

ConsumerMedia & EntertainmentMobility & TransportationSocialSan Francisco, US

BLBobby Loin

Co-investorsRERedpoint VenturesVIVivi NevoDCDCVC (Data Collective)TETenOneTen VenturesSTStanford UniversityTUTuesday Capital

Wedding Spot is an online marketplace where couples can search, compare, and book wedding venues across the United States based on budget, location, style, and guest count.

ConsumerMarketplacesTravel & HospitalitySan Francisco, US

Tina Hoang-To(Executive Officer, Director)

Co-investorsCACanyon Creek CapitalGRGreat Oaks Venture CapitalKEKEC VenturesMAMAIDEN LANE